Drugs / CT-95
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06756035 | Mar 2025 → Dec 2026 expected | cholangiocarcinoma, colorectal cancer, lung adenocarcinoma, malignant epithelial tumor of ovary +3 | Context Therapeutics Inc. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CT-95 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06756035 ↗ |
| Modality | Monoclonal antibody | “MSLN bispecific antibody” NCT06756035 ↗ |
| Route | Intravenous | “administered once weekly (QW) intravenously (IV)” NCT06756035 ↗ |
| Target | MSLN | “MSLN bispecific antibody” NCT06756035 ↗ |